Alzamend Neuro (NASDAQ:ALZN) Price Target Lowered to $20.00 at Ascendiant Capital Markets

Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by Ascendiant Capital Markets from $32.00 to $20.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Alzamend Neuro Trading Up 32.1 %

Shares of ALZN opened at $0.89 on Monday. Alzamend Neuro has a 52 week low of $0.64 and a 52 week high of $15.06. The stock has a fifty day moving average of $1.01 and a 200-day moving average of $1.35.

Alzamend Neuro (NASDAQ:ALZN) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. Sell-side analysts predict that Alzamend Neuro will post -1.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC bought a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro as of its most recent SEC filing. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.